Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-Randomized Study to Assess the Safety and Efficacy of Leniolisib in Japanese Patients With Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Followed By An Open-Label Long-Term Extension

NCT06249997 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT06249997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06249997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-Randomized Study to Assess the Safety and Efficacy of Leniolisib in Japanese Patients With Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Followed By An Open-Label Long-Term Extension
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 3
Overall status
Unknown status
Start date
August 3, 2023
Completion date
March 31, 2025
Enrollment
3 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

apds gene mutation